Back
RESEARCH PLATFORM 2

R.P 2.3 Developing Next-Generation Therapeutic Agents for Glaucoma

DOWNLOAD POSTER
Developing Next-Generation Therapeutic Agents for Glaucoma

Principle Investigators

PolyU
Prof. Chi-wai DO

Prof. Chi-wai DO
Prof. Chuen Thomas LAM

Prof. Chuen Thomas LAM
UWaterloo
Prof. Emmanuel HO

Prof. Emmanuel HO
Co-I
Dr. Jingfang Jennifer BIAN

Dr. Jingfang Jennifer BIAN
Dr. Benqin TANG

Dr. Benqin TANG
Prof. Yan-yin Dennis TSE

Prof. Yan-yin Dennis TSE
Prof. Man-sau WONG

Prof. Man-sau WONG
Prof. Ka-hing WONG

Prof. Ka-hing WONG
Prof. Qian ZHAO

Prof. Qian ZHAO

InnoHK Collaboration

Centre for Chinese Herbal Medicine Drug Development

Aims

To bring next-generation therapeutics for glaucoma to human clinical trials the results of which will enable commercialization by pharmaceutical and food supplement companies

 

Background

Glaucoma is the leading cause of irreversible blindness worldwide. It is incurable and typically characterized by raised intraocular pressure (IOP) ultimately leading to total blindness. Lowering IOP is the only clinical intervention documented to be effective in delaying the progression of glaucoma. However, existing anti-glaucoma treatments have substantial contraindications, undesirable side effects, and drug resistance.

 

Work to be Done

The research team is advancing glaucoma treatment through three innovative approaches:

  • Baicalein-Based Therapy – The flavonoid baicalein has demonstrated IOP-lowering and neuroprotective properties in in vivo and in vitro models, offering dual therapeutic benefits absent in current treatments. 
  • Dietary Supplement Development – The project integrates Nephrokin, a patented plant extract into Bao Ming Drink, a best-selling Amway product known for supporting eye health. 

TCM-Based Prescription (TP) – Oral administration of TP has improved retinal and visual functions in animal glaucoma models. In collaboration with the Centre for Chinese Herbal Medicine Drug Development, the team is optimizing its composition, dosage, and delivery for glaucoma treatment.

 

Benefits

This new glaucoma treatment will provide immediate relief for diagnosed patients while equipping eye care professionals with more effective intraocular pressure control options. Individuals at high risk will gain prophylactic benefits, and the biotech industry will experience growth through emerging market opportunities. Long term, the treatment is expected to reduce global glaucoma-related complications, lower healthcare costs, and improve vision outcomes for millions, benefiting public health systems and society at large.

 

Impact

The project introduces a new class of anti-glaucoma drugs that combine IOP reduction with neuroprotective and anti-inflammatory properties, addressing a critical gap in current therapies. Flavonoid-based treatments and advanced drug delivery systems significantly enhance effectiveness. Additionally, the study explores natural compounds, dietary supplements, and TCM formulations, offering alternative retinal protection solutions where none currently exist, creating new therapeutic classes that go beyond conventional interventions to transform ophthalmic care.

 

 

Learn more about R.P 2.2 Learn more about R.P 2.4

Learn More About Other Research Projects

R.P 1.1 Development and Clinical Validation of AI-Based Software as a Medical Device for Non-Invasive Ophthalmic Imaging and Automated Reporting

Development and Clinical Validation of AI-Based Software as a Medical Device for Non-Invasive Ophthalmic Imaging and Automated Reporting

R.P 1.2 Anti-Myopia Electronic Displays: Making Screens Eye-Safe for Children

Anti-Myopia Electronic Displays: Making Screens Eye-Safe for Children

R.P 1.3 Advanced Technologies for Prediction of Myopia Progression

Advanced Technologies for Prediction of Myopia Progression

R.P 1.4 Targeting Higher-Level Brain Functions for Amblyopia Rehabilitation

Targeting Higher-Level Brain Functions for Amblyopia Rehabilitation

R.P 1.5 Novel Neuromodulation Approaches for Vision Enhancement in Adults

Novel Neuromodulation Approaches for Vision Enhancement in Adults

R.P 2.1 Clinical Translation of a Novel Anti-Microbial Therapy for Eye Infections

Clinical Translation of a Novel Anti-Microbial Therapy for Eye Infections

R.P 2.2 An Organoid Platform and Cell-Based Platform for Ocular Therapeutic Development

An Organoid Platform and Cell-Based Platform for Ocular Therapeutic Development

R.P 2.4 Novel Gene Delivery Platforms for the Treatment of Ocular Disease

Novel Gene Delivery Platforms for the Treatment of Ocular Disease

R.P 2.5 Integrated Dry Eye Diagnosis and Precision Therapies

Integrated Dry Eye Diagnosis and Precision Therapies

R.P 2.6 Development of Ocular Inserts and Aptamer-Based Delivery Vehicles for Sustained Release of Ocular Therapeutics and TCM Products

Development of Ocular Inserts and Aptamer-Based Delivery Vehicles for Sustained Release of Ocular Therapeutics and TCM Products

R.P 3.1 Eye Disease Diagnosis and Treatment Enabled by Novel Retinal Instrumentation

Eye Disease Diagnosis and Treatment Enabled by Novel Retinal Instrumentation

R.P 3.2 Non-Invasive Tear-Based Diagnostic System

Non-Invasive Tear-Based Diagnostic System

R.P 3.3 Development of New-Generation Contact Lenses Using Novel Materials and Additive Manufacturing

Development of New-Generation Contact Lenses Using Novel Materials and Additive Manufacturing

R.P 3.4 Detection of Macular Degeneration and Myopia-Induced Retinal Damage Using Structured Light Technology

Detection of Macular Degeneration and Myopia-Induced Retinal Damage Using Structured Light Technology

R.P 3.5 Extended Reality Visual Intelligence System (XRVIS) for Tele-Visual Assessment and Safety Enhancement for People with Visual Impairment

Extended Reality Visual Intelligence System (XRVIS) for Tele-Visual Assessment and Safety Enhancement for People with Visual Impairment